GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Pre-Tax Income

Incanthera (AQSE:INC) Pre-Tax Income : £-1.55 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Incanthera's pretax income for the six months ended in Sep. 2023 was £-0.62 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was £-1.55 Mil. Incanthera's pretax margin was %.


Incanthera Pre-Tax Income Historical Data

The historical data trend for Incanthera's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Pre-Tax Income Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Pre-Tax Income
-1.23 -1.02 -1.09 -1.45

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Pre-Tax Income Get a 7-Day Free Trial -0.58 -0.50 -0.51 -0.94 -0.62

Competitive Comparison of Incanthera's Pre-Tax Income

For the Biotechnology subindustry, Incanthera's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incanthera's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Incanthera's Pre-Tax Income falls into.



Incanthera Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Incanthera's Pretax Income for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.96+0+0+0+-0.487
=-1.45

Incanthera's Pretax Income for the quarter that ended in Sep. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.615+0+0+0+0
=-0.62

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-1.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incanthera  (AQSE:INC) Pre-Tax Income Explanation

Incanthera's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.615/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incanthera Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Incanthera's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines